Multiple electrode aggregometry and ADP-receptors. Adding ASA (acetylsalicylic acid) reagent to a blood sample reduces the aggregation responses in ASPItest and COLtest. ASA irreversibly inhibits COX1 in platelets, thereby inhibiting the production of TXA2. The ASA Reagent is used as a quality control in the platelet function testing with Multiplate, allowing the assessment of abnormal platelet responses in ASPItest and COLtest. This reagent is used as a quality control in Multiplate platelet function testing. The GPIIb/IIIa antagonist blocks the binding of fibrinogen to the GPIIb/IIIa receptors, preventing the formation of platelet-fibrinogen bonds and resulting in significantly reduced platelet aggregation in response to all
ASA Late Model Series was renamed the ASA Late Model Challenge Series. As part of the splinter of the American Speed Association caused by the 2004 season, the American Speed Association was broken up. The Late Model Series was reacquired by Varney, while other assets were sold to Racing Speed Associates, led by Dennis Huth. On December, 2007, Dennis Huth filed a lawsuit against the ASA Late Model Series seeking to invalidate and cancel the ASA Late Model Series trademark registration. The ASA Late Model Series responded that the lawsuit is frivolous and without merit and plan counter sue Mr. Huth for damages caused